Opportunity ID: 109473

General Information

Document Type:: Grants Notice
Funding Opportunity Number:: RFA-DA-12-010
Funding Opportunity Title:: 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance Use Disorders (DP1)
Opportunity Category:: Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity:: Education
Category Explanation::
Expected Number of Awards::
Assistance Listings Number(s):: 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement:: No
Version:: Synopsis 1
Posted Date:: Jul 29, 2011
Last Updated Date::
Original Closing Date for Applications:: Feb 21, 2012
Current Closing Date for Applications:: Feb 21, 2012
Archive Date:: Mar 23, 2012
Estimated Total Program Funding:: $ 3,000,000
Award Ceiling:: $1,000,000
Award Floor:: $

Eligibility

Eligible Applicants:: Special district governments
Additional Information on Eligibility:: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Additional Information

Agency Name:: National Institutes of Health
Description:: The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of Substance-Use Disorders (SUDs). Through this FOA, the National Institute on Drug Abuse (NIDA) is committed to advancing the development of safe and efficacious medications for the treatment of SUDs stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Medications can be either small molecules or biologics. Biologics include vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the treatment of substance use (i.e., abuse or dependence) disorders and specific clinical manifestations of these disorders such as withdrawal, craving, or relapse.Applications that focus on the development of new formulations of marketed medications that are available for other indications, or new combinations of existing medications that hold promise for the treatment of SUDs, are also within the scope of this RFA.
Link to Additional Information::
Grantor Contact Information:: If you have difficulty accessing the full announcement electronically, please contact:

Version History

Version Modification Description Updated Date
Synopsis 1

Package Status

Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:

Package No: 1

Assistance Listings: 93.279
Competition ID: ADOBE-FORMS-B1
Competition Title: ADOBE-FORMS-B1
Opportunity Package ID: PKG00067771
Opening Date: Jan 21, 2012
Closing Date: Feb 21, 2012
Agency Contact Information:: Grants Info
Who Can Apply:: Organization Applicants
mendatory_forms SF424 (R & R) [V1.2]
PHS 398 Research Plan [V1.3]
PHS 398 Cover Page Supplement [V1.4]
Research And Related Senior/Key Person Profile (Expanded) [V1.2]
Research And Related Other Project Information [V1.3]
Project/Performance Site Location(s) [V1.4]
optional_forms PHS Cover Letter [V1.2]

Packages

Assistance Listings Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions Agency Contact Information: Who Can Apply:
93.279 ADOBE-FORMS-B1 ADOBE-FORMS-B1 PKG00067771 Jan 21, 2012 Feb 21, 2012 View Grants Info Organization Applicants

Related Documents